0001213900-20-008413.txt : 20200402 0001213900-20-008413.hdr.sgml : 20200402 20200402080619 ACCESSION NUMBER: 0001213900-20-008413 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20200402 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200402 DATE AS OF CHANGE: 20200402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 20767401 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 8-K 1 ea120369-8k_nektartherap.htm CURRENT REPORT
0000906709 false 0000906709 2020-04-02 2020-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 2, 2020

 

NEKTAR THERAPEUTICS

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-24006   94-3134940
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

455 Mission Bay Boulevard South

San Francisco, California 94158

(Address of Principal Executive Offices and Zip Code)

 

Registrant's telephone number, including area code: (415) 482-5300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which
registered
Common Stock, $0.0001 par value   NKTR   NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On April 2, 2020, Nektar Therapeutics, a Delaware corporation ("Nektar"), posted on its website (www.nektar.com) a communication from Nektar's Chief Executive Officer regarding COVID-19 (the "COVID-19 Communication"). A copy of the COVID-19 Communication is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

 

The information in this Item 7.01, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the "SEC") made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements which can be identified by words such as: "will," "anticipate," "plan," "may," "implement," "continue," "believe" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential impacts of the COVID-19 coronavirus pandemic on our personnel, their communities, and our business, such as delays or disruptions in our clinical trials, the anticipated timing for the completion of our clinical trials and announcement of clinical trial results, and interruptions in our manufacturing, supply chain, and research and development operations. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the potential impacts of the coronavirus pandemic on our business are based on information, guidelines, and governmental actions that are changing rapidly over time; (ii) the actions we announced to preserve the integrity of our clinical trials may not be effective and may not be fully implemented (if at all) due to circumstances beyond our control; (iii) certain clinical trials in our pipeline are sponsored and operationalized by our collaboration partners and are subject to the risks and uncertainties of those partner's policies and procedures that may continue to evolve over time to address the impact of the coronavirus pandemic; (iv) clinical development has inherent risks and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the indications being studied prior to regulatory approval due to lack of sufficient efficacy, safety considerations or other factors that impact drug development; and (v) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K filed with the SEC on February 28, 2020. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
   
99.1   Communication titled "A Letter from our President & CEO, Howard Robin (updated April 1, 2020)" issued by Nektar Therapeutics on April 2, 2020.

 

1

 

 

SIGNATURES

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  By: /s/ Mark A. Wilson
    Mark A. Wilson
    General Counsel and Secretary
     
  Date:   April 2, 2020

 

 

2

 

 EX-99.1 2 ea120369ex99-1_nektartherap.htm COMMUNICATION TITLED "A LETTER FROM OUR PRESIDENT AND CEO, HOWARD ROBIN (UPDATED APRIL 1, 2020)" ISSUED BY NEKTAR THERAPEUTICS ON APRIL 2, 2020

Exhibit 99.1

 

A Letter from our President & CEO, Howard Robin (updated April 1, 2020)

 

This is an unprecedented time. Nektar and our partners are navigating a complex situation of new and rapidly evolving information and guidelines. The safety and well-being of our fellow employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us. We are also committed to complying with guidance from government and public health officials to stop the spread of COVID-19.

 

Continuing our Important Work on Clinical Trials

 

We have numerous ongoing clinical trials underway in cancer treatment facilities across the globe. These trials are continuing. Our primary focus now is to ensure that each of our trial investigators and their teams can continue to provide superior care and uninterrupted access to treatment to the patients fighting cancer in these studies.

 

We are not able to update any previously communicated timelines for ongoing late-stage clinical studies at this time. However, the evolving situation around COVID-19 and resulting public health guidance measures being put in place will likely delay enrollment of new patients into clinical trials and/or delay our ability to complete timely analyses of data from studies.  The impact that this will have on late-stage clinical study timelines is hard to assess because of the rapidly evolving nature of this situation.  As a result, we do not have an estimate of the length or extent of COVID-19-related delays at this time.  We also caution that regulatory agency guidance and timing of review of impact to clinical trials and data analyses related to COVID-19 is evolving and this could have further impact on timelines and these studies.

 

We currently anticipate that some planned study starts for the second half of 2020 outside oncology could be delayed by a few months depending upon how long COVID-19 precautionary measures remain in effect. In addition, any earlier stage Phase 1/2 clinical studies that are run by us or our partners and are currently enrolling patients in any therapeutic area may be paused or delayed based upon the COVID-19 situation.

 

Preserving the Integrity of Our Clinical Trials

 

In addition to our focus on the well-being of patients currently participating in our trials, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for other patient visit delays caused by limited access to healthcare facilities, to continue monitoring and supporting patients leveraging alternative methods, and to properly record patient event data that may be related to the COVID-19 pandemic.

 

In this respect, we are also incorporating recent direction and flexibility provided by regulatory authorities, including the United States Food and Drug Administration in its March 18, 2020 Guidance (updated March 27, 2020) entitled “FDA Guidance on Conduct of Clinical Trials of Medicinal Products during COVID-19 Pandemic.”  This Guidance is continually being updated by FDA and updates can be found on the FDA’s website at www.fda.gov.  In addition, we may refer to Guidance documents from other regulatory agencies, such as, for example, the European Medicines Agency’s “Implications of coronavirus disease (COVID-19) on methodological aspect of ongoing clinical trials” found on www.ema.europe.eu, which are also continually being updated.  

 

Safeguarding Our Employees and Community

 

We believe we all play an important role in slowing the community spread of COVID-19 and as such, we are closely adhering to all county and state guidelines with respect to the operation of facilities and reinforcing shelter-in-place orders. Essential operations in research, medical and manufacturing are continuing in accordance with the permissions granted under government ordinances.

 

Supporting Our Local Healthcare Workers

 

Our team members are working with our local communities to facilitate donations of personal protective equipment, such as masks and gloves, to healthcare workers. In the San Francisco Bay Area, initial donations are being made to UCSF Medical Center and Kaiser Permanente Santa Clara Medical Center.

 

In Closing

 

We remain committed to serving the needs of our patients and advancing our mission of bringing forth novel therapies for the treatment of cancer and autoimmune disorders. Given the fluidity of the current environment, we are closely monitoring the situation to prepare for and minimize the potential impacts of the COVID-19 pandemic on our overall business.

 EX-101.SCH 3 nktr-20200402.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nktr-20200402_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nktr-20200402_pre.xml XBRL PRESENTATION FILE XML 7 ea120369-8k_nektartherap_htm.xml IDEA: XBRL DOCUMENT 0000906709 2020-04-02 2020-04-02 iso4217:USD shares iso4217:USD shares 0000906709 false 8-K 2020-04-02 NEKTAR THERAPEUTICS DE 0-24006 94-3134940 455 Mission Bay Boulevard South San Francisco CA 94158 (415) 482-5300 false false false false Common Stock, $0.0001 par value NKTR NASDAQ false JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea120369-8k_nektartherap.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "ea120369-8k_nektartherap.htm" ] }, "labelLink": { "local": [ "nktr-20200402_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nktr-20200402_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nktr-20200402.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nktr", "nsuri": "http://nektartherapeutics.com/20200402", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea120369-8k_nektartherap.htm", "contextRef": "From2020-04-02to2020-04-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nektartherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea120369-8k_nektartherap.htm", "contextRef": "From2020-04-02to2020-04-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://nektartherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 10 0001213900-20-008413-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-008413-xbrl.zip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inancial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
Cover
Apr. 02, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 02, 2020
Entity File Number 0-24006
Entity Registrant Name NEKTAR THERAPEUTICS
Entity Central Index Key 0000906709
Entity Tax Identification Number 94-3134940
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 455 Mission Bay Boulevard South
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94158
City Area Code (415)
Local Phone Number 482-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol NKTR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nektartherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea120369-8k_nektartherap.htm ea120369ex99-1_nektartherap.htm nktr-20200402.xsd nktr-20200402_lab.xml nktr-20200402_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false